Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) PT at $51.10

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have been assigned an average rating of “Moderate Buy” from the eleven ratings firms that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $51.10.

A number of research firms recently commented on ANAB. JPMorgan Chase & Co. lifted their target price on AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. HC Wainwright restated a “buy” rating and set a $55.00 price objective on shares of AnaptysBio in a research note on Wednesday, August 14th. Wedbush reiterated an “outperform” rating and issued a $42.00 price objective on shares of AnaptysBio in a research note on Thursday, September 26th. Finally, Truist Financial boosted their target price on shares of AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a research report on Thursday, August 15th.

AnaptysBio Trading Up 0.5 %

Shares of AnaptysBio stock opened at $35.00 on Friday. The firm’s 50 day simple moving average is $35.55 and its two-hundred day simple moving average is $28.38. The firm has a market capitalization of $956.17 million, a price-to-earnings ratio of -5.70 and a beta of -0.29. AnaptysBio has a 12-month low of $13.36 and a 12-month high of $41.31.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.82). AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. The firm had revenue of $10.97 million during the quarter, compared to analyst estimates of $25.85 million. On average, sell-side analysts predict that AnaptysBio will post -6.84 EPS for the current fiscal year.

Insider Buying and Selling at AnaptysBio

In other news, major shareholder Ecor1 Capital, Llc bought 273,972 shares of the stock in a transaction dated Wednesday, August 14th. The shares were acquired at an average cost of $36.50 per share, with a total value of $9,999,978.00. Following the purchase, the insider now directly owns 7,794,996 shares in the company, valued at approximately $284,517,354. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, insider Paul F. Lizzul sold 1,500 shares of the business’s stock in a transaction on Thursday, July 18th. The shares were sold at an average price of $35.00, for a total value of $52,500.00. Following the completion of the sale, the insider now owns 11,618 shares of the company’s stock, valued at approximately $406,630. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Ecor1 Capital, Llc acquired 273,972 shares of the firm’s stock in a transaction on Wednesday, August 14th. The shares were bought at an average cost of $36.50 per share, for a total transaction of $9,999,978.00. Following the completion of the acquisition, the insider now owns 7,794,996 shares of the company’s stock, valued at $284,517,354. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 33,940 shares of company stock valued at $1,251,836. Corporate insiders own 33.70% of the company’s stock.

Institutional Trading of AnaptysBio

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC purchased a new position in AnaptysBio in the 1st quarter valued at about $38,000. Headlands Technologies LLC lifted its position in shares of AnaptysBio by 444.8% in the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock valued at $89,000 after acquiring an additional 2,900 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of AnaptysBio by 66.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 5,123 shares of the biotechnology company’s stock worth $115,000 after acquiring an additional 2,051 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of AnaptysBio during the first quarter worth approximately $222,000. Finally, Algert Global LLC raised its stake in AnaptysBio by 11.8% in the 2nd quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company’s stock valued at $255,000 after purchasing an additional 1,078 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.